Sabah announces free personal insurance for all residents starting next month
KOTA KINABALU, April 9 — The Sabah state government has approved a new group insurance scheme that will provide free personal accident coverage to 3.5 million state residents, Finance Minister Datuk Seri Masidi Manjun announced today.
The scheme, which will be implemented through Progressive Insurance Bhd, a state-owned company, is fully funded by the state government.
"This initiative underscores our commitment to safeguarding the well-being of Sabahans, particularly those in the B40 income group, and easing their financial burden in times of need," Masidi said.
It will automatically enrol all eligible residents, aged between one month and 80 years, for free personal accident coverage valued up to RM10,000. Additionally, a funeral benefit of RM500 will be provided.
The insurance coverage will be offered for three years, from May 1 this year, until April 30, 2028.
Masidi said claims will be processed quickly, with payouts expected within 14 to 30 days upon submission of complete documentation.
Progressive Insurance will release detailed information on eligibility requirements, claim procedures, and necessary documentation, the minister said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Barclays Rises 32.3% YTD: Is it the Right Time to Buy the Stock?
Year to date, shares of Barclays PLC BCS have risen 32.3%. The stock has outperformed the S&P 500 index, the Zacks Finance sector, and the industry. Meanwhile, it has underperformed its close peer, Deutsche Bank DB, while outperforming HSBC Holdings PLC HSBC. Year-to-Date Price Performance Image Source: Zacks Investment Research However, lingering uncertainty around tariff policies continues to pose risks. Given this backdrop, let's assess whether Barclays stock is a lucrative bet or not. Restructuring Efforts to Boost Profitability: Barclays has been taking steps to divest unprofitable/less profitable operations and save expenses through business streamlining, while deploying capital into higher revenue-generating February 2025, Barclays sold its consumer finance business in Germany. Last year, the company transformed its operating divisions and divested its Italian mortgage portfolio and $1.1 billion in credit card these efforts, Barclays recorded gross savings of £1 billion in 2024 and £150 million in the first quarter of 2025. The company aims to achieve gross efficiency savings of £0.5 billion this year. By 2026, management expects total gross efficiency savings to be £2 billion and the cost-to-income ratio to be in the high 50s. Its first-quarter 2025 cost-to-income ratio was 57%.The company is investing these savings in high-growth businesses and markets. This April, Barclays entered into a collaboration with Brookfield Asset Management Ltd. to reshape its payment acceptance business with plans to inject roughly £400 million. In March, the bank had announced a capital injection of more than INR2,300 crore (£210 million) into its India operations, following an injection of almost INR3,000 crore (£300 million) in 2021. Last year, the company acquired Tesco's retail banking business, which complements its existing business. In 2023, Barclays acquired Kensington Mortgage, which bolstered its mortgage redeployment of capital into higher-growth businesses and markets through improving efficiency is a multifaceted approach to boosting profitability. Barclays remains committed to this approach, which is likely to help improve profitability over Capital Distributions: As of March 31, 2025, Barclays' liquidity coverage ratio and net stable funding ratio were 175.3% and 136.2%, respectively, well above the regulatory requirements. This indicates a solid liquidity and funding profile. Thus, a solid balance sheet position supports its enhanced capital company has been paying dividends regularly and plans to keep the total dividend payout stable at the 2023 level, with progressive dividend plans to return at least £10 billion of capital to shareholders between 2024 and 2026 through dividends and share buybacks, with a continued preference for bank has increased dividends six times in the past five years with an annualized growth rate of 45.04%. It has a dividend payout ratio of 28%. Barclays Dividend Yield Image Source: Zacks Investment Research Over the past two months, the Zacks Consensus Estimate for 2025 earnings per share has been revised 6.2% and 3% upward to $2.23 and $2.73, respectively. Estimate Revision Trend Image Source: Zacks Investment Research The Zacks Consensus Estimate for Barclays' 2025 and 2026 earnings implies year-over-year growth of 21.2% and 22.6%, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) BCS stock is currently trading at a forward 12-month price/earnings (P/E) of 7.17X. This is below the industry's 9.4X, reflecting an attractive valuation. Price-to-Earnings F12M Image Source: Zacks Investment Research On the other hand, Deutsche Bank and HSBC have a forward P/E of 8.31X and 8.64X, respectively. This reflects that Barclays is trading at a discount compared to its peers. Entering 2025, a major rebound in mergers and acquisitions (M&As) was expected, with deal-making activities likely to grow in the mid-20s. This optimism stemmed from pent-up demand, stabilizing or declining interest rates, tightening credit spreads, and strong public market valuations. Also, the Trump administration was perceived as business-friendly, with an expected removal of stringent oversight that could mark the end of the prolonged regulatory of these has transpired till now. Deal-making activities have been muted as ambiguity over the tariff and ensuing trade war has resulted in extreme market volatility. These developments have led to economic uncertainty. Against such a backdrop, companies are rethinking their M&A plans despite stabilizing rates and having significant investible management expects investment banking risk-weighted assets (RWAs) to be 50% of the Group RWAs in 2026. Further, the delay in the M&A rebound will impact the IB business of other global banks, including HSBC and Deutsche Bank, impacting revenue growth to some extent. Barclays' restructuring efforts to boost efficiency and redeployment of capital to higher revenue-generating businesses are likely to help the company's financials. Further, a solid liquidity profile enables sustainable capital distributions. Bullish analyst sentiments and attractive valuations are other the bank's core operating performance remains a concern. Net interest income (NII) and net fee, commission, and other income have been witnessing a volatile trend over the last several quarters owing to a tough operating backdrop. Though NII and net fee, commission, and other income rose in 2024 and in the first quarter of 2025, in light of structural hedges and Tesco bank buyout, the uncertainty about the performance of the capital markets might weigh on the company's top line, which makes us apprehensive about its growth prospects. Further, the likelihood of a significant IB rebound this year remains low amid concerns regarding tariff policies, making BCS stock a cautious shareholders may benefit from holding for strong long-term returns, while potential investors should wait for greater macroeconomic clarity before taking a currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Barclays PLC (BCS) : Free Stock Analysis Report Deutsche Bank Aktiengesellschaft (DB) : Free Stock Analysis Report HSBC Holdings plc (HSBC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
Navitus Drug Trend Report: Keeping Costs Low for Plans and Members in an Era of Accelerating Inflation
MADISON, Wis.--(BUSINESS WIRE)-- Navitus, the nation's first transparent, pass-through pharmacy benefit manager (PBM), released its ninth annual Drug Trend Report today, revealing how commercial plan sponsors saved millions in prescription costs while maintaining high-quality member care. 30% of Navitus clients spent less in 2024 than in the previous year, while overall client book of business drug cost trend was managed to 7%. The data shows that medications such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are creating unprecedented financial pressure on plan sponsors as utilization for diabetes treatment increased 26% year-over-year. Overall health spending in the United States is nearly $4.9 trillion and projected to increase nearly 6% annually over the next decade. 1 A subset of this, prescription drug spending, was estimated to be $487 billion in 2024, an industry-wide 11.4% increase over the previous year, compared to 7% for Navitus clients. While the industry faces these escalating cost pressures, our latest Drug Trend Report highlights how Navitus continues to outperform industry trends and save clients money in this challenging environment, including companies such as Progressive Insurance. 'Navitus stands out for its commitment to transparency and managing to lowest net cost, which has significantly benefited Progressive and its members. From the outset, their 100% pass-through model has ensured that we receive the full value of manufacturer rebates and discounts, directly translating to reduced pharmacy costs,' said Heidi Minter, Data Analyst, Benefits & Design Services, Progressive Insurance. The Navitus Drug Trend Report revealed three critical trends influencing the broader industry: 1. 26% increase in GLP-1 RAs use for treatment of type 2 diabetes. While delivering significant clinical benefits, these medications are contributing substantially to pharmaceutical cost increases for benefit plans: Net trend in the diabetes category increased 8.5%, driven by growth in both the use of GLP-1 RAs, including Ozempic, Mounjaro and Trulicity, and a 16% increase in use of sodium-glucose cotransporter-2 inhibitors (SGLT-2s), including Farxiga and Jardiance. The prevalence and cost of GLP-1 RAs and SLGT-2s resulted in an overall unit cost increase of 3.0% for the diabetes category, in spite of the net cost decrease of more than 28% for insulin in 2024. 2. Biosimilars delivered $315 million in savings with a 60% reduction in Humira costs. Targeted immunomodulators (TIMs) treat a wide range of autoimmune disorders, from rheumatoid arthritis and psoriasis to inflammatory bowel diseases. The launch of Humira biosimilar alternatives in 2023 significantly changed the landscape of the category as these clinically-equivalent, much lower cost options were added to formulary. After adding biosimilars to formulary, Navitus took a decisive step to lower costs further by removing Humira from formulary in June 2024. This led to key results including: Over $315 million in upfront cost savings. 60% reduction in net costs per claim. 3. Specialty medication utilization increased 12%. Approximately 75% of new drug approvals have been for specialty or medical specialty agents, and that trend is expected to continue in the next two years. Key factors included: Oncology net trend increased more than 13%, driven by both higher utilization and unit cost: Utilization of newer breast cancer treatments (Kisqali, Verzenio) increased 20%, driving overall cost. In specialty dermatology, Dupixent (dupilumab) emerged as the most rapidly growing drug of 2024. The category saw a net trend increase of more than 45% and Dupixent represented 96% of category cost and utilization. While increased use of newer, more expensive agents like Kesimpta created upward pressure within the multiple sclerosis category, generics represented more than 50% of prescriptions filled at 10% of the cost. Expand 'Our annual Drug Trend Report confirms we were able to control year-over-year costs for commercial clients - both large and small - and deliver savings greater than the estimated industry averages,' said Sharon Faust, PharmD, MBA, CSP, Chief Pharmacy Officer, Navitus Health Solutions. 'Deploying generic-first strategies, facilitating adoption of new biosimilars, ensuring 100% pass-through of negotiated rebates and discounts, and supporting clinically appropriate prescribing, utilization and formulary management remain core to our focus.' Access the Navitus Drug Trend Report executive summary here: Methodology: The Navitus drug trend is calculated by comparing the net total cost per-member per-month (PMPM) for 2024 to that for 2023. Net cost PMPM represents full-year (Q1-Q4) data for total member copays and plan paid amounts minus manufacturer rebates and fees. This value is divided by the total number of members and by 12 months of the year. The data represents employer plan sponsors and health plans. In order to be included organizations must have been with Navitus for two full calendar years. * Due to varying coverage decisions by clients, GLP-1s for weight loss were not included in the Drug Trend Report, yet they still warrant thoughtful consideration and conversation in the overall picture of trend and future decisions. The DTR only represents prescriptions under the pharmacy benefit. 40% of Rx spend is through the medical benefit and warrants careful consideration by plans. Sources: About Navitus Navitus remains the nation's first transparent, pass-through pharmacy benefit manager (PBM). It uniquely brings clarity to drug pricing and takes costs out of the drug supply chain. Unlike traditional PBMs that generate profit by retaining an undisclosed portion of rebates and discounts negotiated with drug manufacturers and pharmacies, Navitus passes along the complete savings to clients, enabling them to make medication more affordable for their members. Navitus was established more than 20 years ago by Navitus Health Solutions, LLC, a pioneering pharmacy solutions company. The organization delivers a range of services through portfolio brands including Navitus, Lumicera, Archimedes. Owned by SSM Health and Costco, Navitus Health Solutions serves over 18 million lives across 800 clients including employers, unions, government plans, payors and health systems. For more information, please visit
New York Post
2 days ago
- New York Post
Controversial tax credit to save Downtown Manhattan on verge of getting renewed: sources
The push by real estate dealmakers for Albany to renew a controversial tax-credit critical to saving Downtown Manhattan turned into a real 'cliffhanger' – but appears poised for approval, The Post has learned. The citywide Relocation Employment Assistance Program and a similar one specifically for Lower Manhattan, known as LM-REAP, provide tax credits of up to $3,000 per employee to companies that relocate from out of the city or from parts of Manhattan to designated areas in the outer boroughs or to Downtown Manhattan. Tens of thousands of jobs and the future of scores of Lower Manhattan office buildings would be at risk if the little-known REAP programs were not renewed when they expire on June 30, according to landlords and business advocates. 3 Tens of thousands of jobs and the future of scores of Lower Manhattan office buildings would be at risk if the little-known REAP programs were not renewed when they expire on June 30, according to landlords and business advocates. Christopher Sadowski The measures were left out of the state's budget plan announced in April and appeared doomed as lawmakers in the state Senate and Assembly were set to escape for their summer break. But there was movement on an extension over the weekend, a knowledgeable Albany source told The Post on Monday. 'It finally got key approvals in the Assembly, and it's looking good tomorrow in the Senate, which was where the hangup was,' the source said. Michael Gianaris, the State Senate Deputy Majority Leader from Queens, among others, had argued that REAP cost the city too much in foregone taxes — up to $33 million by 2033, according to the Department of Finance — to justify the economic benefits the additional jobs would bring. 3 Michael Gianaris, the State Senate Deputy Majority Leader from Queens, had argued that REAP cost the city too much in foregone taxes to justify the economic benefits the additional jobs would bring. Hans Pennink But renewing the program 'is critical to COVID recovery, preserving affordable office space and promoting job growth in small and medium-size businesses,' argued a rep for the Alliance for Downtown. Supporters say LM-REAP costs the city a negligible $5 million a year — a pittance weighed against the tax benefits it helps generate in property and incomes taxes, although those figures are harder to quantify. REAP began in 1987 to stem an exodus of tenants to New Jersey. The Lower Manhattan plan, launched in 2003, is credited with supporting 16,000 city jobs and helping to lease hundreds of thousands of square feet of office space in a market that's had more downs than ups since 9/11. One source predicted a fresh wave of flight to New Jersey if REAP is allowed to die. 'They're actively recruiting New York businesses with programs offering up to $8,000 per job and $250,000 relocation grants. It's clear that if New York steps back, New Jersey will step in,' the source said. The REAP renewals, as well as creation of a new program called the Relocation Assistance Credit for Employees (RACE), are backed by Gov. Kathy Hochul. But fearing that the measures would be allowed to die, local congressional representatives threw their voices into the fray. 3 The REAP renewals are backed by Gov. Kathy Hochul. Lev Radin/Shutterstock Gregory Meeks, Grace Meng, Ritchie Torres, Thomas Suozzi and Adriano Espaillat wrote to State Senate Majority Leader Andrea Stweart-Cousins and Assembly Speaker Carl Heastie that with 'record high office vacancies downtown, 'Now is not the time to end LM-REAP.' The REAP programs have also brought jobs to Dumbo, MetroTech and the Navy Yard in Brooklyn and to Long Island City in Queens. But the heat's mostly on Lower Manhattan, where more than 20% of nearly 90 million square feet of offices in the nation's second-largest commercial district stand vacant — and it might get worse. 'I believe the numbers being cited for current and future vacancies are too low, especially on Water Street,' said one Downtown executive who asked for anonymity told The Post. 'The REAP program is essential to keeping downtown competitive.'
